Menu Home Search

important message from GPC Chairman -Change to vaccine scheduling

Date sent: Wednesday 30 December 2020

All Senior Partners, CDs and Practice Managers

Dear Colleagues

As you will have seen, MHRA have today given approval for the use of the Oxford/AZ vaccine in the UK. This will start to be used next week, but only in limited amounts. The first doses will be given in a hospital setting to monitor for any adverse reaction and we expect some practices will receive a limited number of doses later in the week, primarily for care home residents. For the next few weeks the Pfizer vaccine is likely to remain the main vaccine for our patients.

The CMOs have just issued a press statement, copied below, about the scheduling of covid vaccinations. Please share this with your practices as they need to be made aware as soon as possible that this change which will impact on those patients booked in for a second dose next month. We are in discussion with NHSEI today about the significant implications for practices that this change will have and will update you as soon as we can.

I've also copied a link to the MHRA slides used in their press conference this morning.

Best wishes

Richard

Slides to accompany coronavirus data briefing: 30 December

Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines

Organisation:

Department of Health and Social Care

Type:

Press Release

Date:

30 December 2020

Joint clinical advice from the 4 UK Chief Medical Officers on the prioritisation of first doses of the coronavirus (COVID-19) vaccines.

It is excellent news that the Medicines and Healthcare products Regulatory Agency (MHRA) has today authorised the AstraZeneca (Oxford) vaccine for deployment across the UK.

The MHRA authorisation includes conditions that the AstraZeneca (Oxford) vaccine should be administered in 2 doses, with the second dose given between 4 and 12 weeks after the first. The MHRA has also clarified that for the Pfizer/BioNTech vaccine, the interval between doses must be at least 3 weeks. For both vaccines, data provided to MHRA demonstrate that while efficacy is optimised when a second dose is administered, both offer considerable protection after a single dose, at least in the short term. For both vaccines the second dose completes the course and is likely to be important for longer term protection.

The Joint Committee on Vaccination and Immunisation (JCVI) has subsequently recommended that as many people on the JCVI priority list as possible should sequentially be offered a first vaccine dose as the initial priority. They have advised that the second dose of the Pfizer/BioNTech vaccine may be given between 3 to 12 weeks following the first dose, and that the second dose of the AstraZeneca (Oxford) vaccine may be given between 4 to 12 weeks following the first dose. The clinical risk priority order for deployment of the vaccines remains unchanged and applies to both vaccines. Both are very effective vaccines.

The 4 UK Chief Medical Officers agree with the JCVI that at this stage of the pandemic prioritising the first doses of vaccine for as many people as possible on the priority list will protect the greatest number of at risk people overall in the shortest possible time and will have the greatest impact on reducing mortality, severe disease and hospitalisations and in protecting the NHS and equivalent health services. Operationally this will mean that second doses of both vaccines will be administered towards the end of the recommended vaccine dosing schedule of 12 weeks. This will maximise the number of people getting vaccine and therefore receiving protection in the next 12 weeks.

Based on JCVI’s expert advice, it is our joint clinical advice that delivery plans should prioritise delivering first vaccine doses to as many people on the JCVI Phase 1 priority list in the shortest possible timeframe. This will allow the administration of second doses to be completed over the longer timeframes in line with conditions set out by the independent regulator, the MHRA and advice from the JCVI. This will maximise the impact of the vaccine programme in its primary aims of reducing mortality and hospitalisations and protecting the NHS and equivalent health services.

The JCVI has also amended its previous highly precautionary advice on COVID-19 vaccines and pregnancy or breastfeeding. Vaccination with either vaccine in pregnancy should be considered where the risk of exposure SARS-CoV2 infection is high and cannot be avoided, or where the woman has underlying conditions that place her at very high risk of serious complications of COVID-19, and the risks and benefits of vaccination should be discussed. Those who are trying to become pregnant do not need to avoid pregnancy after vaccination, and breastfeeding women may be offered vaccination with either vaccine following consideration of the woman’s clinical need for immunisation against COVID-19. The UK Chief Medical Officers agree with this advice.

Documents

Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020

PDF, 215KB, 16 pages Annex A: COVID-19 vaccine and health inequalities: considerations for prioritisation and implementation

 

Kind Regards

Jill

Jill Hellens

Executive Director

Somerset LMC

TEL: 01823 331428

Fax:01823 338561

www.somersestlmc.co.uk

Follow us on Twitter

Download the App

General Practice in Somerset Great Place Great Potential

We have updated our privacy policies on both the Somerset LMC and Somerset GP Education trust websites.

 

Related guidance and emails...

Covid-19 - Vaccination Programme

Covid-19 - Vaccination Programme The BMA have produced guidance on the Covid-19 vaccine programme that can be seen at...

BMA position on 2nd dose of vaccination for at-risk patients in England

All GPs and Practice managers BMA says decision to delay follow-up dose of Pfizer vaccine 'grossly unfair' to thousands of at-risk...

Vaccine Update - Public Health England, Fluenz Tetra availability 2018/2019

If you are a provider of flu vaccination for children through general practice or the schools programme in England, please take some...

National Flu Campaign 2020/21

Guidance on how to locally manage held flu vaccine stock in Primary Care Providers and NHS Trusts The National Flu Immunisation...

National Flu Immunisation Programme 2018/19

NEW: PHE leaflet for over 65s flu vaccine - October 2018 Public Health England have produced a leaflet for patients aged over 65 about...

Do We Need to See Patients for Travel Advice?

Travel vaccines are part of additional services of the new GMS contract. When the new contract was introduced in 2004 a number of the...

Vaccine update: issue 315, December 2020

Vaccine Update Issue - 315 - December 2020 ** COVID-19 vaccination special** This COVID-19 vaccination programme special edition...

Vaccine update: issue 311, August 2020

Vaccine update: issue 311, August 2020 This month's edition features: JCVI interim report on priority groups for immunisation during...

Inactivated influenza vaccines for the childhood flu vaccination programme a

The 2 vaccines that are available to order for the 16-17 season are: • Inactivated Influenza Vaccine (Split Virion) BP (TIV) – for...

Somerset LMC Weekly Update Friday 18th December 2020

Sent to all Somerset GPs and Practice Managers This and previous updates are available here Message from LMC Chairman Dr Karen...